Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Università Cattolica Del Sacro Cuore, Facoltà di Medicina, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Clin Microbiol Infect. 2022 Aug;28(8):1155.e1-1155.e4. doi: 10.1016/j.cmi.2022.04.008. Epub 2022 Apr 21.
People with Down syndrome (DS) are particularly vulnerable to coronavirus disease 2019 (COVID-19) and show altered immune response to vaccination. We aimed to evaluate the immune response of a group of adults with DS treated with standard regimens of SARS-CoV-2 vaccine as compared with an age- and sex-matched group of persons without DS.
We compared antibody responses between 42 subjects with DS (41.6 ± 10.8 years, 57% male), and an age- and sex-matched comparison group of healthy health care workers (HCW) (41.4 ± 8.8 years, 54.8% male) after SARS-CoV-2 vaccination with the standard regimen of BNT162b2 mRNA COVID-19. Receptor binding domain (RBD) IgG antibodies were assessed at 4 time points (baseline, 21 days after the first dose, 21 days after the second dose, and 6 months after the first dose) with Siemens SARS-CoV-2 IgG (COV2G) antibody test.
We observed significantly different antibody responses at all time points after vaccination (HCW vs. DS: 7.9 ± 3.9 vs. 1.4 ± 3.6 IU/mL at 21 days after first dose; 358.5 ± 3.8 vs. 38.1 ± 3.0 IU/mL at 21 days after second dose; 34.6 ± 2.4 vs. 7.9 ± 3.1 IU/mL at 6 months after vaccination) and a significantly different time course of decline in antibody titers between the two groups.
Subjects with DS have a valid antibody response to SARS-CoV-2 vaccination. However, this response is lower than that of subjects in the HCW group. This finding could indicate a more rapid decline in the protective effects of the vaccination in subjects with DS and could suggest that people with DS may benefit from a booster dose of vaccine.
唐氏综合征（DS）患者特别容易感染 2019 年冠状病毒病（COVID-19），并且对疫苗接种的免疫反应发生改变。我们旨在评估一组接受标准 SARS-CoV-2 疫苗方案治疗的 DS 成人患者与一组年龄和性别相匹配的无 DS 患者的免疫反应。
我们比较了 42 名 DS 患者（41.6±10.8 岁，57%为男性）和年龄及性别匹配的健康医护人员（HCW）（41.4±8.8 岁，54.8%为男性）在接受 BNT162b2 mRNA COVID-19 标准方案接种 SARS-CoV-2 疫苗后的抗体反应。使用西门子 SARS-CoV-2 IgG（COV2G）抗体检测在 4 个时间点（基线、第一剂后 21 天、第二剂后 21 天和第一剂后 6 个月）评估受体结合域（RBD）IgG 抗体。
我们观察到接种疫苗后所有时间点的抗体反应均有显著差异（HCW 与 DS：第一剂后 21 天分别为 7.9±3.9 和 1.4±3.6 IU/mL；第二剂后 21 天分别为 358.5±3.8 和 38.1±3.0 IU/mL；接种后 6 个月分别为 34.6±2.4 和 7.9±3.1 IU/mL），并且两组之间的抗体滴度下降的时间过程也存在显著差异。
DS 患者对 SARS-CoV-2 疫苗接种有有效的抗体反应。然而，这种反应低于 HCW 组。这一发现可能表明 DS 患者的疫苗保护作用下降更快，并可能表明 DS 患者可能受益于疫苗加强剂量。
